A prospective cohort study by Preston et al. found no difference in either prostate cancer incidence or PCM, adjusting for multiple socioeconomic factors, 5-ɑ reductase inhibitor use, and diagnostic intensity with PSA and biopsies. This evidence concerns the gene KLK3 and prostate carcinoma.